Skip to main content
Erschienen in: Breast Cancer 3/2016

14.01.2015 | Original Article

Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types

verfasst von: Jochem König, Reyn van Ewijk, Kathrin Kuhr, Heinz Schmidberger, Achim Wöckel, Rolf Kreienberg, Maria Blettner

Erschienen in: Breast Cancer | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Aim

Treatment–outcome associations often differ substantially between observational studies (OSs) and randomized controlled trials (RCTs). We investigate causes, focusing on radiotherapy (RT) effects in early breast cancer treatment, to better understand each study type’s merits.

Methods and materials

We systematically analyzed three potential causes, by comparing data from a large OS with results from two previously published meta-analyses of RCTs: differences in patient populations combined with heterogeneous treatment effects, non-random treatment decisions in OSs, and differences in therapy administration.

Results

RT–survival associations were considerably stronger in our OS than in the RCTs, e.g., a hazard rate for overall survival after breast-conserving therapy of 0.57 in the OS vs 0.90 in the RCTs. The first proposed reason has limited relevance: patient populations differed considerably, but effect heterogeneity between patient groups was limited. The second reason does explain part of the difference: in the OS treatment decisions (being nonrandomized) and prospects differed with patient characteristics. Notably, patients with early recurrences or mortality are generally excluded from RCTs. Their inclusion in OSs leads to stronger treatment–outcome associations.

Conclusion

RCTs and OSs each have their own merits. While RCTs have their undisputed benefits, results from OSs that indicate that RT effects in early breast cancer are even stronger than those reported in RCTs should not be ignored.
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and on 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and on 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRef
2.
Zurück zum Zitat EBCTCG. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:771–84.CrossRef EBCTCG. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:771–84.CrossRef
3.
Zurück zum Zitat Ford HT, Coombes RC, Gazet JC, et al. Long-term follow-up of a randomised trial designed to determine the need for irradiation following conservative surgery for the treatment of invasive breast cancer. Ann Oncol. 2006;17:401–8.CrossRefPubMed Ford HT, Coombes RC, Gazet JC, et al. Long-term follow-up of a randomised trial designed to determine the need for irradiation following conservative surgery for the treatment of invasive breast cancer. Ann Oncol. 2006;17:401–8.CrossRefPubMed
4.
Zurück zum Zitat Holli K, Hietanen P, Saaristo R, et al. Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J Clin Oncol. 2009;27:927–32.CrossRefPubMed Holli K, Hietanen P, Saaristo R, et al. Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J Clin Oncol. 2009;27:927–32.CrossRefPubMed
5.
Zurück zum Zitat Potter R, Gnant M, Kwasny W, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:334–40.CrossRefPubMed Potter R, Gnant M, Kwasny W, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:334–40.CrossRefPubMed
6.
Zurück zum Zitat Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18:1220–9.PubMed Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18:1220–9.PubMed
7.
Zurück zum Zitat Gebski V, Lagleva M, Keech A, et al. Survival effects of post-mastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst. 2006;98:26–38.CrossRefPubMed Gebski V, Lagleva M, Keech A, et al. Survival effects of post-mastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst. 2006;98:26–38.CrossRefPubMed
8.
Zurück zum Zitat Kyndi M, Sorensen FB, Knudsen H. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.CrossRefPubMed Kyndi M, Sorensen FB, Knudsen H. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.CrossRefPubMed
9.
Zurück zum Zitat Vandenbroucke JP. Why do the results of randomised and observational studies differ? BMJ. 2011;343:d7020.CrossRefPubMed Vandenbroucke JP. Why do the results of randomised and observational studies differ? BMJ. 2011;343:d7020.CrossRefPubMed
11.
Zurück zum Zitat Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLOS Med. 2011;8(5):1–13.CrossRef Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLOS Med. 2011;8(5):1–13.CrossRef
12.
Zurück zum Zitat McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ. 1999;319:312–5.CrossRefPubMedPubMedCentral McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ. 1999;319:312–5.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286(7):821–30.CrossRefPubMed Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286(7):821–30.CrossRefPubMed
14.
Zurück zum Zitat Rothwell PM. Treating individuals 1 external validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82–93.CrossRefPubMed Rothwell PM. Treating individuals 1 external validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82–93.CrossRefPubMed
15.
Zurück zum Zitat Shrier I, Boivin JF, Steele RJ, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 2007;166(10):1203–9.CrossRefPubMed Shrier I, Boivin JF, Steele RJ, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 2007;166(10):1203–9.CrossRefPubMed
17.
Zurück zum Zitat Altonji JG, Elder TE, Taber CR. Selection on observed and unobserved variables: assessing the effectiveness of catholic schools. J Polit Econ. 2005;113(1):151–84.CrossRef Altonji JG, Elder TE, Taber CR. Selection on observed and unobserved variables: assessing the effectiveness of catholic schools. J Polit Econ. 2005;113(1):151–84.CrossRef
18.
Zurück zum Zitat Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–92.CrossRefPubMedPubMedCentral Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–92.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–86.CrossRefPubMed Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–86.CrossRefPubMed
20.
Zurück zum Zitat Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet. 2009;373(9671):1233–5.CrossRefPubMed Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet. 2009;373(9671):1233–5.CrossRefPubMed
Metadaten
Titel
Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types
verfasst von
Jochem König
Reyn van Ewijk
Kathrin Kuhr
Heinz Schmidberger
Achim Wöckel
Rolf Kreienberg
Maria Blettner
Publikationsdatum
14.01.2015
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 3/2016
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-014-0579-2

Weitere Artikel der Ausgabe 3/2016

Breast Cancer 3/2016 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.